‘Remdesivir will be sold for US$520 (S$724) per vial, or US$3,120 per treatment course, to hospitals for treatment of patients with private insurance, according to the Department of Health and Human Services and Gilead Sciences, the drug's manufacturer.’
Read here (Straits Times, June 30, 2020)
